Zobrazeno 1 - 10
of 2 924
pro vyhledávání: '"“budget impact” analysis"'
Autor:
Reckers-Droog V; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. reckers@eshpm.eur.nl., Enzing J; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.; National Health Care Institute, Diemen, The Netherlands., Brouwer W; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Publikováno v:
The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2024 Nov; Vol. 25 (8), pp. 1449-1459. Date of Electronic Publication: 2024 Feb 27.
Autor:
Mohanty, Sangita1, Nayak, Amaresh Kumar1 aknayak20@yahoo.com, Tripathi, Rahul1, Bhaduri, Debarati1, Chatterjee, Dibyendu1, Kumar, Anjani1, Shahid, Mohammad1, Kumar, Upendra1, Munda, Sushmita1, Mandi, Gaban1, Pathak, Himanshu2
Publikováno v:
International Journal of Sustainable Development & World Ecology. 2023, Vol. 30 Issue 8, p869-882. 14p.
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background An increasing number of orphan medicinal products (OMPs) are being included in social health insurance schemes, significantly improving access to medicines for patients with rare diseases. However, high-priced OMPs are still not c
Externí odkaz:
https://doaj.org/article/1fb671b47d1740a89727bb13096dea6c
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2155-2177 (2024)
Abstract Introduction Japan will be transitioning from the free-of-charge COVID-19 vaccination program to annual periodic vaccination under a national immunization program for old adults and high-risk patients from 2024 fall/winter season. The policy
Externí odkaz:
https://doaj.org/article/8bed62a875af4e43bab0846949c3e920
Publikováno v:
Journal of Management in Engineering; Jul2024, Vol. 40 Issue 4, p1-14, 14p
Autor:
Djuric O; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Centre for Environmental, Nutritional and Genetic Epidemiology (CREAGEN), University of Modena and Reggio Emilia, Modena, Italy., Deandrea S; Pavia Health Protection Agency, Pavia, Italy., Mantellini P; ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy., Sardanelli F; IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy., Venturelli F; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Montemezzi S; Radiology Unit - University Hospital of Verona, Verona, Italy., Vecchio R; Pavia Health Protection Agency, Pavia, Italy., Bucchi L; IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' - IRST S.r.l., Meldola, Forlì-Cesena, Italy., Senore C; AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy., Giordano L; AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy., Paci E; Italian Cancer League, LILT, Florence, Italy., Bonifacino A; Fondazione IncontraDonna, Rome, Italy., Calabrese M; Breast Unit. IRCCS-Policlinico San Martino, Genoa, Italy., Caumo F; Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy., Degrassi F; Associazione Nazionale Donne Operate al Seno - ANDOS, Milan, Italy., Sassoli De' Bianchi P; Department of Health, Emilia-Romagna Region Administration, Bologna, Italy., Battisti F; ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy., Zappa M; ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy., Pattacini P; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Campari C; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Nitrosi A; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Di Leo G; IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy., Frigerio A; AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy., Magni V; IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy., Fornasa F; Breast Unit ULSS9 Scaligera, Ospedale Fracastoro, San Bonifacio, Verona, Italy., Romanucci G; Breast Unit ULSS9 Scaligera, Ospedale Fracastoro, San Bonifacio, Verona, Italy., Falini P; ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy., Auzzi N; ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy., Armaroli P; AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy., Giorgi Rossi P; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy. paolo.giorgirossi@ausl.re.it.
Publikováno v:
La Radiologia medica [Radiol Med] 2024 Sep; Vol. 129 (9), pp. 1288-1302. Date of Electronic Publication: 2024 Aug 20.
Publikováno v:
Internal Revenue Bulletin. 1/13/2020, Issue 2020-3, p296-326. 31p.
Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Autor:
A. Alshahrani, S. Al-Aqeel, M. Alshahrani, S. Alqahtani, S.T. Alhawwashi, M.S. Al-Nasser, M. Zaitoun
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 12, Pp 102204- (2024)
Objectives: To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer. Methods: A BIA model was developed to calculate the expected financial impact under two sc
Externí odkaz:
https://doaj.org/article/11fac21e86ed40018e5d7aa3395628e0
Autor:
S. К. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 17, Iss 1, Pp 22-29 (2024)
Objective: to evaluate the pharmacoeconomic efficacy of “atezolizumab + bevacizumab + paclitaxel + carboplatin” drug combination compared to “pembrolizumab + pemetrexed + carboplatin” combination in adult patients with non-small cell lung can
Externí odkaz:
https://doaj.org/article/557de269226e485abb3da016a266dd6b
Autor:
John Paul Caesar delos Trinos, Luc E. Coffeng, Fernando Garcia, Jr., Vicente Belizario, Jr., Virginia Wiseman, Caroline Watts, Susana Vaz Nery
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 50, Iss , Pp 101162- (2024)
Summary: Background: School-based targeted preventive chemotherapy (PC), the primary strategy for soil-transmitted helminth (STH) control, typically focusing on primary schoolchildren, was expanded to secondary school students in the Philippines in 2
Externí odkaz:
https://doaj.org/article/6879a2f3060d4c33951d45fca8e4f9bb